Ian Ingram is a Deputy Managing Editor at MedPage Today. He covers a range of topics within medicine and healthcare, focusing on consumer health, drugs and medication, public health, and the healthcare system, with a particular interest in alternative medicine. Ian's work has been featured in Knowledia, ExBulletin, MedPage Today, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ian Ingram's coverage is primarily focused on healthcare and pharmaceuticals, with a particular emphasis on clinical trial results, FDA approvals, and drug treatments for cancer and leukemia. He frequently cites data in his articles, indicating an interest in evidence-based reporting.
Pitching to Ian should involve providing access to newly released or exclusive clinical trial data, insights from key opinion leaders in the field of oncology or pharmaceuticals regarding recent developments in cancer treatment or FDA approval processes.
It's important to note that Ian does not have a specific geographic focus but covers international healthcare and pharmaceutical topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— Substantial EFS improvement with selpercatinib in RET fusion-positive disease
Oral mezigdomide's benefit shown in patients mostly refractory to lenalidomide and anti-CD38
Adjuvant approach will need confirmation from ongoing phase III trial, says expert
CHICAGO -- A randomized trial testing the addition of selinexor (Xpovio) to ruxolitinib (Jakafi) for myelofibrosis only met one of its two primary endpoints, yet the combination also showed a potential survival benefit.
By: Ian Ingram
Novel gedatolisib is currently under review at FDA for wild-type patients
By: Ian Ingram
News and commentary from the world of gastroenterology and hepatology
By: Ian Ingram
News and commentary from the world of gastroenterology and hepatology
— Non-antibiotic approach can help deal with non-healing necrotic skin and soft tissue wounds
By: Ian Ingram
News and commentary from the world of gastroenterology and hepatology
Studies have shown baloxavir to be a standout among antivirals commonly used for influenza
